

What is Claimed is:

1. A conjugate comprising Substance P or an analog thereof, and a protein that inhibits protein synthesis.
2. The conjugate of claim 1, wherein the conjugate comprises an analog of Substance P.
3. The conjugate of claim 1, wherein the Substance P has the amino acid sequence at the N-terminus
CYGGGGGGGRPKPQQFFSarLMet(0₂)-amide (SEQ ID NO. 1).
4. The conjugate of claim 1, wherein the Substance P has the amino acid sequence at the N-terminus CYGGGGGGGRPKPQQFFGLM-
amide (SEQ ID NO. 2).
5. The conjugate of claim 1, wherein the protein is Saporin.
6. The conjugate of claim 1, wherein the protein is in a recombinant form.
7. A conjugate comprising a protein that inhibits protein synthesis and an antibody that recognizes the NK-1 receptor.
8. The conjugate of claim 1, wherein the protein is ricin A chain, gelonin, pokeweed antiviral protein, or a bacterial toxin, or any fragment thereof, that inhibits protein synthesis.
9. The conjugate of claim 1, wherein the protein is diptheria toxin or pseudomonas aeruginosa toxin, or any fragment thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 1 and a pharmaceutically acceptable carrier.
- 5 11. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 2 and a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 3 and a pharmaceutically acceptable carrier.
- 10 13. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 4 and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 8 and a pharmaceutically acceptable carrier.
- 15 15. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 9 and a pharmaceutically acceptable carrier.
16. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 10 so as to reduce the perception of pain by the subject.
- 20 17. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount

of the pharmaceutical composition of claim 11 so as to reduce the perception of pain by the subject.

18. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 12 so as to reduce the perception of pain by the subject.

19. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 13 so as to reduce the perception of pain by the subject.

20. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 14 so as to reduce the perception of pain by the subject.

21. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 15 so as to reduce the perception of pain by the subject.

22. A method of selectively destroying NK-1 receptor expressing cells in a subject comprising administering to the subject an effective amount of the conjugate of claim 1 so as to selectively destroy NK-1 receptor expressing cells.

23. A method of treating a subject with cancer comprising administering to the subject an effective amount of the

pharmaceutical composition of claim 10 so as to treat the cancer.

24. A method for treating a NK-1 receptor associated disorder in a subject, which comprises administering to the subject an amount of the pharmaceutical composition of claim 10 thereby treating the disorder associated with the NK-1 receptor.